VERU News and Press, Veru Inc. From 08/30/23

MIAMI, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndrome (ARDS), today announced that Mitchell Steiner, M.D., Chai...

2023-08-18 10:19:27 ET Gainers: Aditxt ( ADTX ) +50% . AlloVir ( ALVR ) +18% . Agenus ( AGEN ) +7% . Veru ( VERU ) +7% . Akari Therapeutics ( AKTX ) +6% . Losers: Evelo Biosciences ( EVLO ) -37% . Diffusi...

2023-08-10 14:30:21 ET Veru Inc. (VERU) Q2 2023 Earnings Conference Call August 09, 2023 04:30 PM ET Company Participants Sam Fisch - Executive Director, Investor Relations & Corporate Communications Mitchell Steiner - Chairman, Chief Executive Officer & Pres...

2023-08-10 06:34:05 ET Veru press release ( NASDAQ: VERU ): Q3 GAAP EPS of $0.07 beats by $0.27 . Revenue of $3.34M (-65.2% Y/Y) misses by $6.88M . For further details see: Veru GAAP EPS of $0.07 beats by $0.27, revenue of $3.34M misses by $6.88M

Company receives further regulatory clarity from FDA on Phase 3 ENABLAR-2 study. Potential for enobosarm +/- abemaciclib accelerated approval pathway in metastatic breast cancer, if successful based on new FDA Guidance Company plans to expand sabizabulin Phase 3 confirmatory study t...

MIAMI, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for breast cancer and for viral acute respiratory distress syndrome (ARDS), today announced it will host a conference call and audio webcast...

2023-07-20 16:40:52 ET Summary Increasing operational losses and decreased net revenues necessitate immediate financing in my view. Its largest customer defaulted on payments and filed for bankruptcy. I believe the company's future is uncertain with no catalysts for stock rall...

2023-07-18 10:13:56 ET Gainers: iCAD ( ICAD ) +31% . Biophytis ( BPTS ) +27% . Hyperfine ( HYPR ) +15% . Cabaletta Bio ( VERU ) +12% . Mind Medicine (MindMed) ( MNMD ) +10% . Losers: Lixte Biotechnology ( LIXT ) ...

Research grants from U.S. Department of Defense (DoD) and National Cancer Institute’s Research Project Grant (NCI R01) awarded to UTHSC to study new types of targeting agents for multiple cancer indications with significant unmet need Aggregate funding for UTHSC exceeds $10M for ...

2023-06-07 15:08:00 ET Veru ( NASDAQ: VERU ) has been upgraded by Jefferies from underperform to hold, due in part to the firm believing the stock was oversold and upcoming data from a Phase 2B clinical trial for Veru's breast cancer drug enobosarm. The investment bank said that...